003017.SHE Zhejiang Dayang Biotech Group Co
- Market cap
- CNY 2.27B
- P/E
- 25.3x
- P/B
- 1.91x
- ROE
- 7.9%
- Dividend yield
- 2.40%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 003017.SHE undervalued?
Graham number003017.SHE trades 46.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Dayang Biotech Group Co fundamental analysis
No fundamental analysis for Zhejiang Dayang Biotech Group Co yet.
Zhejiang Dayang Biotech Group Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Dayang Biotech Group Co
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium bicarbonate, ammonium chloride, manufactures and sales bicarbonate food and feed additives; veterinary drugs; potassium bicarbonate; and ammonium chloride. It also provides 2-chloro-6-fluorobenzoic acid, fluorobenzaldehyde, and fluorobenzyl chloride. In addition, it offers aminopropionate …
Full company profileZhejiang Dayang Biotech Group Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Dayang Biotech Group Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 441M | 555M | 584M | 622M | 678M | 783M | 1.06B | 919M | 910M | 1.05B | 1.06B |
| Gross Profit | 105M | 135M | 148M | 154M | 164M | 150M | 144M | 162M | 171M | 239M | 227M |
| Operating Income | 17.3M | 57.6M | 78.7M | 87.1M | 102M | 79.3M | 59.2M | 56.3M | 75.4M | 123M | 103M |
| EBITDA | 61.7M | 84.5M | 104M | 119M | 133M | 125M | 123M | 122M | 146M | 184M | 103M |
| Net Income | 28.8M | 50.3M | 70.8M | 79.5M | 91.6M | 70.0M | 80.7M | 50.0M | 63.7M | 99.9M | 91.1M |
| EPS | 0.61 | 0.93 | 1.21 | 1.26 | 1.38 | 0.83 | 0.99 | 0.62 | 0.78 | 0.99 | 0.90 |
| Balance Sheet | |||||||||||
| Total Assets | 467M | 513M | 602M | 646M | 1.23B | 1.37B | 1.51B | 1.55B | 1.65B | 1.82B | 1.99B |
| Total Liabilities | 237M | 175M | 161M | 148M | 271M | 384M | 523M | 538M | 600M | 682M | 833M |
| Shareholders' Equity | 229M | 338M | 441M | 498M | 958M | 991M | 985M | 1.01B | 1.05B | 1.13B | 1.15B |
| Cash & Short-term Investments | 36.0M | 41.2M | 30.3M | 53.1M | 439M | 412M | 428M | 382M | 394M | 441M | 353M |
| Total Debt | 147M | 75.0M | 23.0M | 23.0M | 49.9M | 180M | 282M | 249M | 358M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 84.6M | 48.6M | 38.8M | 113M | 112M | -35.2M | 91.9M | 182M | 66.2M | 160M | - |
| Capital Expenditure | 50.9M | 26.7M | 44.1M | 61.8M | 125M | 93.4M | 105M | 104M | 63.4M | 76.4M | 188M |
| Free Cash Flow | 33.7M | 21.9M | -5.28M | 51.3M | -12.3M | -129M | -12.8M | 78.8M | 2.74M | 83.7M | -85.9M |
| Ratios | |||||||||||
| ROE | 12.6% | 14.9% | 16.1% | 16.0% | 9.6% | 7.1% | 8.2% | 5.0% | 6.1% | 8.8% | 7.9% |
| ROA | 6.2% | 9.8% | 11.8% | 12.3% | 7.5% | 5.1% | 5.4% | 3.2% | 3.9% | 5.5% | 4.6% |
| Net Profit Margin | 6.5% | 9.1% | 12.1% | 12.8% | 13.5% | 8.9% | 7.6% | 5.4% | 7.0% | 9.6% | 8.6% |
| Debt to Equity | 0.64x | 0.22x | 0.05x | 0.05x | 0.05x | 0.18x | 0.29x | 0.25x | 0.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Dayang Biotech Group Co dividends
- Dividend yield
- 2.40%
- Forward dividend
- 0.60 CNY
- Payout ratio
- 54.7%
- Ex-dividend date
- Sep 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 54.7M | 0.54 | 54.7% |
| 2024 | CNY 42.7M | 0.52 | 67.0% |
| 2023 | CNY 42.6M | 0.53 | 85.2% |
| 2022 | CNY 34.3M | 0.42 | 42.5% |
| 2021 | CNY 36.0M | 0.43 | 51.4% |
| 2020 | CNY 13.5M | 0.20 | 14.7% |
| 2019 | CNY 24.0M | 0.38 | 30.1% |
| 2018 | CNY 23.4M | 0.40 | 33.1% |
| 2017 | CNY 27.3M | 0.50 | 54.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 26, 2026.
Who owns Zhejiang Dayang Biotech Group Co
- Insiders 35.62%
- Institutions 2.79%
- Public & others 61.59%
- Shares outstanding 101M
- Free float 66.3M
Zhejiang Dayang Biotech Group Co company profile
- Company name
- Zhejiang Dayang Biotech Group Co
- Ticker
- 003017.SHE
- ISIN
- CNE100004736
- Exchange
- Shenzhen Stock Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 771
- Fiscal year end
- December
- Address
- No. 22 Chaoyang Road, Jiande, China, 311616
- Phone
- 86 57 1641 56868
- Website
- dyhg.com
About Zhejiang Dayang Biotech Group Co
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium bicarbonate, ammonium chloride, manufactures and sales bicarbonate food and feed additives; veterinary drugs; potassium bicarbonate; and ammonium chloride. It also provides 2-chloro-6-fluorobenzoic acid, fluorobenzaldehyde, and fluorobenzyl chloride. In addition, it offers aminopropionate hydrochloride. Further, it engages in the wholesale and retail of pharmaceutical intermediates; and research and development of industrial enzyme preparations and biological feeds. The company was founded in 1976 and is based in Jiande, China.
Zhejiang Dayang Biotech Group Co management
10- Ms. Xujun ChenGM, CFO & Director · born 1978
- Mr. Xianyu WangExecutive VP & Vice Chairman · born 1960
- Mr. Guoping WangAssistant GM, Head of Technology Department & Director · born 1974
- Mr. Xuping XuHead of Securities and Legal Department & Board Secretary · born 1965
- Mr. Yongsheng QiuDeputy GM & Director · born 1960
- Mr. Jiang Feng BaoDeputy GM & Head of Production Support Department · born 1976
- Mr. Jianfei YeDeputy General Manager · born 1974
- Lijuan JinHead of Accounting Department
- Mr. Wei Hong LiHuman Resources Department Officer · born 1977
- Mr. Yuan LiDeputy Director of Human Resources Department · born 1986